JERUSALEM (Reuters) - Teva Pharmaceutical Industries reported a slightly higher third-quarter profit, aided by sales of its Austedo treatment for Huntington’s Disease. The company also stated that the production in Israel was not affected by the country’s war with Hamas in Gaza.
The world’s largest generic drugmaker announced on Wednesday that it earned 60 cents per diluted share, excluding one-time items, in the July-September quarter. This is an increase from 59 cents per share in the same period last year.
Revenue increased by 7% to $3.9 billion, with Austedo sales rising by 30% in North America to $339 million. Sales of the migraine drug Ajovy increased by 8%, and generic medicine sales in North America saw a 15% increase.
“The continued strong performance of Austedo, Ajovy, and our generics business contributed to growth in all geographies,” said Chief Executive Officer Richard Francis. “Based on these consistently strong results, we are raising our revenue outlook for 2023 for the second consecutive quarter.”
Analysts had predicted earnings of 61 cents per share, excluding one-time items, for the…
2023-11-08 07:40:16
Original from finance.yahoo.com
rnrn